SEC Form 4 · accession 0000899243-18-003150
SOLENO THERAPEUTICS INC · SLNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steinar J Engelsen
Director
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001484565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3,F1,F2 | Feb 5, 2018 | A | 8,109 | $1.7263 | A | 41,831 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.
- F2The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on February 2, 2018, or $1.7263.
- F3Resigned from the Board of Directors effective December 31, 2017. Fees incurred for 2017 Board and committee services.